DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The "Diphtheria - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 7, 4, 3, 2 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Key Topics Covered

Introduction Report Coverage Diphtheria - Overview Diphtheria - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Diphtheria - Therapeutics Assessment Assessment by Target Assessment by Route of Administration Assessment by Molecule Type Diphtheria - Companies Involved in Therapeutics Development

Companies Mentioned

Beijing Minhai Biotechnology Co Ltd Biological E Ltd Boryung Pharmaceutical Co Ltd Cadila Healthcare Ltd Chongqing Zhifei Biological Products Co Ltd GC Pharma GlaxoSmithKline Plc Indian Immunologicals Ltd Kaketsuken LG Chem Ltd Panacea Biotec Ltd Sanofi Sanofi Pasteur SA Serum Institute of India Ltd Shantha Biotechnics Pvt Ltd Wockhardt Ltd

For more information about this report visit https://www.researchandmarkets.com/research/jjlmgg/diphtheria?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005559/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 05:58 AM/DISC: 06/06/2018 05:58 AM

http://www.businesswire.com/news/home/20180606005559/en